Image

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

Recruiting
18-45 years
All
Phase N/A

Powered by AI

Overview

The goal of this observational study is to identify differential traits in spontaneous migraine attacks that can help us predict the response to treatment with sumatriptan.

Participants will be asked to register the headache characteristics before and after taking sumatriptan and whether the treatment was effective or not during four migraine attacks.

Description

There is still an unmet need in acute migraine treatment, some patients don't respond properly to acute medication.

There are some interindividual differences in clinical characteristics of migraine attacks. These differences may determine the response to acute treatment. Describing the phenotypical differences between patients who are responders and patients non-responders will allow us to offer a personalized treatment.

The aim of the study is to determine which characteristics are associated with a response or a non-response to acute treatment with sumatriptan.

Participants will be asked to register the headache characteristics and accompanying symptoms during 4 spontaneous migraine attacks and its response to treatment with sumatriptan.

Eligibility

Inclusion Criteria:

  • Migraine with or without aura diagnosis according to ICHD-3 criteria
  • <8 migraine days per month
  • Be able to read, write and understand instructions.
  • Have internet access and mail address
  • Signing of the informed consent

Exclusion Criteria:

  • Active preventive treatment for migraine
  • Active medication with an effect over the central nervous system
  • Serious physical or psychiatric condition
  • Cardiovascular or hepatic disease
  • Pregnant or breastfeeding women
  • Any triptan contraindication
  • Severe migraine attacks without previous response to triptans or NSAIDs

Study details
    Migraine Disorders

NCT06503848

Hospital Universitari Vall d'Hebron Research Institute

14 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.